| Population 2014 |
99 million |
| | |
| | | | | | | |
| Estimates of TB burden * 2014 |
Number (thousands) |
Rate
(per 100 000 population) |
| Mortality (excludes HIV+TB) |
10 |
(9–11) |
10 |
(9.1–11) |
| Mortality (HIV+TB only) |
0.08 |
(0.055–0.11) |
0.08 |
(0.06–0.11) |
| Prevalence (includes HIV+TB) |
410 |
(360–470) |
417 |
(367–471) |
| Incidence (includes HIV+TB) |
290 |
(250–320) |
288 |
(254–324) |
| Incidence (HIV+TB only) |
2.5 |
(2–3.2) |
2.6 |
(2–3.2) |
| |
|
|
|
|
| Case detection, all forms (%) |
85 |
(76–97) |
|
|
| | |
| | | | | | | |
| Estimates of MDR-TB burden * 2014 |
|
New |
|
Retreatment |
| % of TB cases with MDR-TB |
2 |
(1.4–2.7) |
21 |
(16–29) |
MDR-TB cases among notified pulmonary
TB cases |
4 600 |
(3 300–6 300) |
6 500 |
(4 700–8 700) |
| | |
| | | | | | | |
| TB case notifications 2014 |
New ** |
Relapse |
| Pulmonary, bacteriologically confirmed |
92 991 |
|
6 277 |
| Pulmonary, clinically diagnosed |
139 950 |
|
|
| Extrapulmonary |
4 161 |
|
|
| |
|
|
|
| Total new and relapse |
243 379 |
|
|
| Previously treated, excluding relapses |
24 057 |
|
|
| Total cases notified |
267 436 |
|
|
| | |
| | | | | | | |
| Among 97 578 new and relapse cases: | | | | | | |
| 12 191 (12%) cases aged under 15 years; male:female ratio: 1.8 | | | |
| | | | | | | |
| Reported cases of RR-/MDR-TB 2014 |
New |
Retreatment |
Total ** |
| Cases tested for RR-/MDR-TB |
4 415 (5%) |
20 196 (67%) |
27 287 |
| Laboratory-confirmed RR-/MDR-TB cases |
|
|
3 000 |
| Patients started on MDR-TB treatment *** |
|
|
2 680 |
| | |
| | | | | | | |
| TB/HIV 2014 |
Number |
(%) |
| TB patients with known HIV status |
53 354 |
(20) |
| HIV-positive TB patients |
108 |
(<1) |
| HIV-positive TB patients on co-trimoxazole preventive therapy (CPT) |
20 |
(19) |
| HIV-positive TB patients on antiretroviral therapy (ART) |
53 |
(49) |
| HIV-positive people screened for TB |
5 995 |
|
| HIV-positive people provided with IPT |
|
|
| | |
| | | | | | | |
| Treatment success rate and cohort size |
(%) |
Cohort |
| New and relapse cases registered in 2013 |
(90) |
216 250 |
| Previously treated cases, excluding relapse, registered in 2013 |
(86) |
2 924 |
| HIV-positive TB cases, all types, registered in 2013 |
|
|
| RR-/MDR-TB cases started on second-line treatment in 2012 |
(43) |
1 798 |
| XDR-TB cases started on second-line treatment in 2012 |
(10) |
10 |
| | |
| | | | | | | |
| Laboratories 2014 |
|
| Smear (per 100 000 population) |
2.6 |
| Culture (per 5 million population) |
1.1 |
| Drug susceptibility testing (per 5 million population) |
0.2 |
| Sites performing Xpert MTB/RIF |
84 |
| Is second-line drug susceptibility testing available? |
Yes, in country |
| | |
| | | | | | | |
| Financing TB control 2015 |
|
| National TB programme budget (US$ millions) |
106 |
| % Funded domestically |
23% |
| % Funded internationally |
39% |
| % Unfunded |
37% |
| | |
| | | | | | | |
| * Ranges represent uncertainty intervals | | | | | |
| ** Includes cases with unknown previous TB treatment history | | | | |
| *** Includes patients diagnosed before 2014 and patients who were not laboratory-confirmed as having | |
| RR-/MDR-TB | | | | | | | |
| | | | | | | |